器质性心脏病心房颤动患者的药物治疗

doi:10.3969/j.issn.1004-583X.2016.01.007

临床荟萃 ›› 2016, Vol. 31 ›› Issue (1): 27-29.doi: 10.3969/j.issn.1004-583X.2016.01.007

器质性心脏病心房颤动患者的药物治疗

齐书英¹, 袁晓红²

1.白求恩国际和平医院心血管内科, 河北石家庄 050082;
2.石家庄市裕华区妇幼保健站,河北石家庄 050081

收稿日期:2015-10-28 出版日期:2016-01-05 发布日期:2016-04-19
通讯作者: 齐书英,Email:qsy304@126.com
作者简介:齐书英,女,医学博士,白求恩国际和平医院心血管内科副主任、主任医师,河北医科大学教授,硕士研究生导师。国家考试中心心血管内科专科医师准入考试及心血管疾病介入诊疗考试心律失常介入专业考官、中华医学会起搏电生理分会女医师联盟委员、中国生物医学工程学会心律分会医学教育委员会委员、中国生物医学工程学会心律分会青年委员、中国心电学学会委员、解放军心血管内科学专业青年委员会常委、北京军区心血管专业委员会常委、河北省医学会心血管专业委员会委员、河北省中老年保健协会心脏健康教育专业委员会副主任委员、河北省女医师协会会员、河北省医疗事故鉴定专家组成员。发表学术论文70余篇,获得军队或河北省科技进步或医疗成果奖11项。

Drug therapy of atrial fibrillation with organic heart disease

Qi Shuying¹, Yuan Xiaohong²

1.Department of Cardiology, Bethune International Peace Hospital, Shijiazhuang 050082, China;
2.Yuhua District Health Center for Women and Children, Shijiazhuang 050081, China

Received:2015-10-28 Online:2016-01-05 Published:2016-04-19
Contact: Qi Shuying,Email:qsy304@126.com

摘要/Abstract

摘要： 心房颤动(房颤)是临床常见的心律失常之一,致残、致死率高。房颤的治疗策略包括抗凝预防血栓栓塞、转复和维持窦性心律、心室率控制,药物治疗是房颤治疗的基础,但器质性心脏病合并房颤的处理有其特殊性,本文对器质性心脏病合并房颤的药物治疗予以综述。

关键词: 心房颤动, 冠心病, 药物疗法

Abstract: Atrial fibrillation (AF) is one of the most common types of arrhythmia with high disability rate and mortality rate in clinical practice. Treatment strategies of AF include anticoagulation to prevent thromboembolism, conversion and sinus rhythm maintenance and ventricular rate control. However, the process of atrial fibrillation with organic heart disease has its particularity. This article reviews the medication treatment for AF with organic heart disease.

Key words: atrial fibrillation, coronary disease, drug therapy

中图分类号:

R541.75

齐书英, 袁晓红. 器质性心脏病心房颤动患者的药物治疗[J]. 临床荟萃, 2016, 31(1): 27-29.

Qi Shuying, Yuan Xiaohong. Drug therapy of atrial fibrillation with organic heart disease[J]. Clinical Focus, 2016, 31(1): 27-29.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.007

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/27

参考文献

[1] 胡大一,孙艺红.心房颤动的流行病学和治疗现状[J].中华全科医师杂志,2006,5(1):5-7.
[2] Wong CX, Lau DH, Sanders P. Atrial fibrillation epidemic and hospitalizations: how to turn the rising tide [J].Circulation,2014,129(23):2361-2363.
[3] Lip GY,Brechin CM,Lane DA.The global burden of atrial fibrillation and stroke:a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe[J]. Chest,2012,142(6):1489-1498.
[4] Romero I, Nedios S, Kriatselis C. Diagnosis and management of atrial fibrillation: an overview[J]. Cardiovasc Ther,2014,32(5):242-252.
[5] Calkins H, Kuck KH, Cappato R, et al.2012HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design[J]. Europace,2012,33(2):171-257.
[6] Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial [J].JAMA,2014,312(19):1988-1998.
[7] Pedersen OD,Abildstrm SZ,Ottesen MM,et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction[J]. Eur Heart J,2006,27(3):290-295.
[8] Ruiz-Nodar JM,Marín F,Roldn V, et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? [J]. Circ Cardiovasc Interv,2012,5(4):459-466.
[9] Dewilde WJ,Oirbans T,Verheugt FW,et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial[J]. Lancet,2013,381(9872):1107-1115.
[10] 中华医学会心血管病分会. 抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2013,41(3):183-194.
[11] Moser M,Olivier CB,Bode C.Triple antithrombotic therapy in cardiac patients: more questions than answers[J]. Eur Heart J,2014,35(4):216-223.
[12] 马长生,刘少伟. 心力衰竭合并心房颤动的治疗策略进展[J]. 内科理论与实践,2014,9(1):11-15.
[13] van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF[J]. Circ Heart Fail,2013,6(4): 740-747.
[14] Sanjeev S, April S, Albert LW, et al. Cardiovascular Outcomes in the AFFIRM Trial: An Assessment of Individual Antiarrhythmic Drug Therapies compared to Rate Control Using Propensity Score Matched Analyses [J]. J Am Coll Cardiol,2011,58(19):1975-1985.
[15] Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure [J]. N Engl J Med,2008,358(25): 2667-2677.
[16] Torp Pedersen C, Mller M, Bloch Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction [J]. N Engl J Med,1999,341(12): 857- 865.
[17] Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high risk permanent atrial fibrillation [J]. N Engl J Med,2011,365(24): 2268-2276.
[18] Kber L, TorpPedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure [J]. N Engl J Med,2008,358(25): 2678-2687.
[19] Fuster V, Rydén LE, Cannom DS,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Forceon Practice Guidelines and the European Society of Cardiology Committee for PracticeGuidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) [J]. Eur Heart J,2006,27(16): 1979-2030.
[20] 吴书林,刘洋. 心房颤动的“律”、“率”治疗[J]. 中国医刊,2014,49(1):4-6.
[21] Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Europace,2010,12(10):1360-1420.
[22] Rienstra M, Damman K, Mulder BA, et al. Beta blockers and outcome in heart failure and atrial fibrillation [J]. JACC Heart Fail,2013,1(1): 2128.
[23] Cohn JN. Inotropic therapy for heart failure: paradise lost[J]. Eur Heart J,2009,30(24): 2965- 2966.
[24] Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin analysis from the AFFIRM study [J].Eur Heart J,2013,34(20):1481-1488.
[25] Van Veldhuisen DJ, Van Gelder IC, Ahmed A, et al. Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? [J]. Eur Heart J,2013,34(20):1468-1470.
[26] Li TJ,Zang WD,Chen YL,et al.Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a metaanalysis[J]. Int J Clin Pract,2013,67(6):536-543.
[27] Dabrowski R,Borowiec A,Smolis-Bak E,et al.Effect of combined spironolactone-beta-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation(SPIR-AF study)[J].Am J Cardiol,2010,106(11):1609-1614.
[28] January CT,Wann LS,Alpert JS,et al.2014 AHA /ACC /HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21) :e1-e76.

器质性心脏病心房颤动患者的药物治疗

Drug therapy of atrial fibrillation with organic heart disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	李雯琳, 张志. 心房颤动患者左心耳形态结构和功能与左心耳血栓及心源性卒中的关系研究进展[J]. 临床荟萃, 2024, 39(2): 168-171.
[3]	魏宇涵, 赵亚楠, 张桂彬, 吴雨晴, 董博华, 扈家源, 杨文琦. 单核细胞/高密度脂蛋白胆固醇比值、红细胞分布宽度、尿酸与冠心病患者冠状动脉病变严重程度的相关性[J]. 临床荟萃, 2023, 38(9): 796-801.
[4]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[5]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[6]	宗廷妮, 戴光荣, 赵晓宇, 李瑞风, 柴聪敏. 代谢相关脂肪性肝病靶向药物治疗进展[J]. 临床荟萃, 2023, 38(4): 373-376.
[7]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[8]	刘亚鑫, 郭岚, 王泽凯, 牛凯. 慢性肾脏病合并骨质疏松症治疗的研究进展[J]. 临床荟萃, 2023, 38(12): 1146-1149.
[9]	师佩华, 林彦琳, 毕丽妨. NLR、PLR及MLR与2型糖尿病合并冠心病患者的相关性研究[J]. 临床荟萃, 2023, 38(11): 996-1001.
[10]	张上仕, 朱红艳, 李楠, 陈鹰熙. 冠心病合并2型糖尿病患者冠状动脉病变与胰岛素抵抗的相关性分析[J]. 临床荟萃, 2023, 38(1): 46-49.
[11]	伊鑫, 刘灿章, 刘强, 王聪, 高腾, 闫杰. 冠心病患者合并焦虑抑郁对冠状动脉斑块成分及性质的影响[J]. 临床荟萃, 2023, 38(1): 50-54.
[12]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[13]	马静红, 杨倩, 贾永建, 党懿. 心房颤动导管消融围术期不间断新型口服抗凝剂和不间断华法林抗凝导致心脏压塞风险的荟萃分析[J]. 临床荟萃, 2022, 37(9): 773-778.
[14]	张海福, 叶向晴, 陈者旭, 陈施鉴, 杨栋, 张邢炜. 适量运动对心房颤动患者预后的影响:系统综述与Meta分析[J]. 临床荟萃, 2022, 37(6): 485-489.
[15]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.